A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Lurbinectedin (Primary)
- Indications Advanced breast cancer; Biliary cancer; Carcinoma; Endometrial cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Head and neck cancer; Neuroendocrine tumours; Small cell lung cancer
- Focus Therapeutic Use
- Acronyms Basket
- Sponsors PharmaMar
- 24 Apr 2017 Planned number of patients changed from 250 to 325.
- 07 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 02 Jun 2015 New trial record